GyneFix® - LNG: Preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system

D. Wildemeersch; M. Dhont; M. Temmerman; W. Delbarge; E. Schacht; M. Thiery

doi:10.3109/13625189909043475

GyneFix® - LNG: Preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system

D. Wildemeersch
, M. Dhont
, M. Temmerman
, W. Delbarge
, E. Schacht
, M. Thiery

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

A novel intrauterine contraceptive drug delivery system derived from the conventional GyneFix® intrauterine implant system is described and the preliminary results in 22 women are discussed. The first objective of the development of the GyneFix-levonorgestrel system was to reduce menstrual bleeding, whether or not related to the effect of copper, by combining a shortened version of the standard GyneFix implant, having a copper surface area of 200 mm², with a system for the sustained intrauterine delivery of levonorgestrel. The results of this initial observational study indicate that the GyneFix-levonorgestrel system, apart from being well tolerated, is safe and effective. The levonorgestrel component appears to have a beneficial effect on the amount of bleeding. A study on menstrual blood loss will be carried out to substantiate this assumption.

Original language	English (UK)
Pages (from-to)	15-19
Number of pages	5
Journal	European Journal of Contraception and Reproductive Health Care
Volume	4
Issue number	1
DOIs	https://doi.org/10.3109/13625189909043475
Publication status	Published - 1999
Externally published	Yes

Keywords

GyneFix
Intrauterine device
Levonorgestrel
Menstrual bleeding
Sexually transmitted infections

Access to Document

10.3109/13625189909043475

Cite this

@article{753c56a2935e4bd196a8d6230fa5103b,

title = "GyneFix{\textregistered} - LNG: Preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system",

abstract = "A novel intrauterine contraceptive drug delivery system derived from the conventional GyneFix{\textregistered} intrauterine implant system is described and the preliminary results in 22 women are discussed. The first objective of the development of the GyneFix-levonorgestrel system was to reduce menstrual bleeding, whether or not related to the effect of copper, by combining a shortened version of the standard GyneFix implant, having a copper surface area of 200 mm2, with a system for the sustained intrauterine delivery of levonorgestrel. The results of this initial observational study indicate that the GyneFix-levonorgestrel system, apart from being well tolerated, is safe and effective. The levonorgestrel component appears to have a beneficial effect on the amount of bleeding. A study on menstrual blood loss will be carried out to substantiate this assumption.",

keywords = "GyneFix, Intrauterine device, Levonorgestrel, Menstrual bleeding, Sexually transmitted infections",

author = "D. Wildemeersch and M. Dhont and M. Temmerman and W. Delbarge and E. Schacht and M. Thiery",

year = "1999",

doi = "10.3109/13625189909043475",

language = "English (UK)",

volume = "4",

pages = "15--19",

journal = "European Journal of Contraception and Reproductive Health Care",

issn = "1362-5187",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - GyneFix® - LNG

T2 - Preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system

AU - Wildemeersch, D.

AU - Dhont, M.

AU - Temmerman, M.

AU - Delbarge, W.

AU - Schacht, E.

AU - Thiery, M.

PY - 1999

Y1 - 1999

N2 - A novel intrauterine contraceptive drug delivery system derived from the conventional GyneFix® intrauterine implant system is described and the preliminary results in 22 women are discussed. The first objective of the development of the GyneFix-levonorgestrel system was to reduce menstrual bleeding, whether or not related to the effect of copper, by combining a shortened version of the standard GyneFix implant, having a copper surface area of 200 mm2, with a system for the sustained intrauterine delivery of levonorgestrel. The results of this initial observational study indicate that the GyneFix-levonorgestrel system, apart from being well tolerated, is safe and effective. The levonorgestrel component appears to have a beneficial effect on the amount of bleeding. A study on menstrual blood loss will be carried out to substantiate this assumption.

AB - A novel intrauterine contraceptive drug delivery system derived from the conventional GyneFix® intrauterine implant system is described and the preliminary results in 22 women are discussed. The first objective of the development of the GyneFix-levonorgestrel system was to reduce menstrual bleeding, whether or not related to the effect of copper, by combining a shortened version of the standard GyneFix implant, having a copper surface area of 200 mm2, with a system for the sustained intrauterine delivery of levonorgestrel. The results of this initial observational study indicate that the GyneFix-levonorgestrel system, apart from being well tolerated, is safe and effective. The levonorgestrel component appears to have a beneficial effect on the amount of bleeding. A study on menstrual blood loss will be carried out to substantiate this assumption.

KW - GyneFix

KW - Intrauterine device

KW - Levonorgestrel

KW - Menstrual bleeding

KW - Sexually transmitted infections

UR - https://www.scopus.com/pages/publications/0032588024

U2 - 10.3109/13625189909043475

DO - 10.3109/13625189909043475

M3 - Article

C2 - 10367191

AN - SCOPUS:0032588024

SN - 1362-5187

VL - 4

SP - 15

EP - 19

JO - European Journal of Contraception and Reproductive Health Care

JF - European Journal of Contraception and Reproductive Health Care

IS - 1

ER -

GyneFix® - LNG: Preliminary clinical experience with a copper and levonorgestrel-releasing intrauterine system

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this